Alternative Solvents for Extractables and Leachables Evaluation - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Alternative Solvents for Extractables and Leachables Evaluation
The authors examine alternative solvents for evaluation of process components that provide extraction equivalence and do not interfere chromatographically.


Pharmaceutical Technology
Volume 37, Issue 8, pp. 51-53

Conclusion
When comparing extraction efficiency between the various solvents for extractable screening studies, it is recommended that IPA be used as a worst-case solvent in cases for which surfactants are of interest. In addition, the ions from the mass spectra of compounds detected in the IPA extraction solvent can then be used to perform extracted ion analysis on the extracts that contain surfactants. Use of an alternate solvent such as IPA ensures that potential extractable compounds are not missed in the surfactant extractions during initial extractables screening.

Jennifer M. Roark, Mai N. Jacques, PhD, Erica J. Tullo, PhD, Andrew T. Blakinger, and Thomas C. Lehman*, PhD are all in the Method Development & Validation group at Eurofins Lancaster Laboratories, 2425 New Holland Pike, Lancaster, PA 17601, USA, 1.717.656.2300, http://www.lancasterlabspharm.com/.

*To whom all correspondence should be addressed.

References

1. FDA, Guidance for Industry: Container Closure Systems for Packaging Human Drugs and Biologics (Rockville, MD, May 1999).

2. CFR Title 21, Part 211.65 (Government Printing Office, Washington, DC, 2006).

3. Bio-Process Systems Alliance, Recommendations for Testing and Evaluation of Extractables from Single-Use Process Equipment, (Washington, DC, 2010).

4. Bio-Process Systems Alliance, BioProcess Intl. 5 (11) 36-49 (2007).

5. T. C. Lehman, "Evaluation of Model Solvents for Generating Extractable Compound Profiles from Single-Use Systems," presentation at AAPS Annual Meeting and Exposition (Washington DC, 2011).

Join the discussion

What issues are you having with extractables and leachables evaluation?

Post your comments on http://www.pharmtech.com/linkedin


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Source: Pharmaceutical Technology,
Click here